841 related items for PubMed ID: 23440694
1. Evaluation of intravenous immunoglobulin resistance and coronary artery lesions in relation to Th1/Th2 cytokine profiles in patients with Kawasaki disease.
Wang Y, Wang W, Gong F, Fu S, Zhang Q, Hu J, Qi Y, Xie C, Zhang Y.
Arthritis Rheum; 2013 Mar; 65(3):805-14. PubMed ID: 23440694
[Abstract] [Full Text] [Related]
2. Predictors for intravenous immunoglobulin resistance and coronary artery lesions in Kawasaki disease.
Xie T, Wang Y, Fu S, Wang W, Xie C, Zhang Y, Gong F.
Pediatr Rheumatol Online J; 2017 Mar 21; 15(1):17. PubMed ID: 28320400
[Abstract] [Full Text] [Related]
3. A comparison of serum IL6 and CRP levels with respect to coronary changes and treatment response in Kawasaki disease patients: a prospective study.
Nandi A, Pal P, Basu S.
Rheumatol Int; 2019 Oct 21; 39(10):1797-1801. PubMed ID: 31302740
[Abstract] [Full Text] [Related]
4. Association of lower eosinophil-related T helper 2 (Th2) cytokines with coronary artery lesions in Kawasaki disease.
Kuo HC, Wang CL, Liang CD, Yu HR, Huang CF, Wang L, Hwang KP, Yang KD.
Pediatr Allergy Immunol; 2009 May 21; 20(3):266-72. PubMed ID: 19438983
[Abstract] [Full Text] [Related]
5. The role of serum lipid in predicting coronary artery lesions and intravenous immunoglobulin resistance in Kawasaki disease: a cohort study.
Zhang H, Cai J, Zhang R, Shuai S, Tang M, Ju R, Hu Y, Zuo T, Yang Y.
J Int Med Res; 2024 May 21; 52(5):3000605241252115. PubMed ID: 38713460
[Abstract] [Full Text] [Related]
6. Inflammatory cytokines as predictors of resistance to intravenous immunoglobulin therapy in Kawasaki disease patients.
Sato S, Kawashima H, Kashiwagi Y, Hoshika A.
Int J Rheum Dis; 2013 Apr 21; 16(2):168-72. PubMed ID: 23773640
[Abstract] [Full Text] [Related]
7. Predictive Value of Serum Lipid for Intravenous Immunoglobulin Resistance and Coronary Artery Lesion in Kawasaki Disease.
Shao S, Zhou K, Liu X, Liu L, Wu M, Deng Y, Duan H, Li Y, Hua Y, Wang C.
J Clin Endocrinol Metab; 2021 Sep 27; 106(10):e4210-e4220. PubMed ID: 33837779
[Abstract] [Full Text] [Related]
8. N-terminal pro-brain natriuretic peptide and risk of coronary artery lesions and resistance to intravenous immunoglobulin in Kawasaki disease.
Yoshimura K, Kimata T, Mine K, Uchiyama T, Tsuji S, Kaneko K.
J Pediatr; 2013 Jun 27; 162(6):1205-9. PubMed ID: 23290510
[Abstract] [Full Text] [Related]
9. Osteoprotegerin serum levels in Kawasaki disease: an additional potential marker in predicting children with coronary artery involvement.
Simonini G, Masi L, Giani T, Piscitelli E, Cimaz R, Vierucci S, Brandi ML, Falcini F.
J Rheumatol; 2005 Nov 27; 32(11):2233-8. PubMed ID: 16265708
[Abstract] [Full Text] [Related]
10. Interleukin-18 and coronary artery lesions in patients with Kawasaki disease.
Weng KP, Hsieh KS, Huang SH, Ou SF, Lai TJ, Tang CW, Lin CC, Ho TY, Liou HH, Ger LP.
J Chin Med Assoc; 2013 Aug 27; 76(8):438-45. PubMed ID: 23769880
[Abstract] [Full Text] [Related]
11. Inflammatory cytokine profiles during Cyclosporin treatment for immunoglobulin-resistant Kawasaki disease.
Hamada H, Suzuki H, Abe J, Suzuki Y, Suenaga T, Takeuchi T, Yoshikawa N, Shibuta S, Miyawaki M, Oishi K, Yamaga H, Aoyagi N, Iwahashi S, Miyashita R, Honda T, Onouchi Y, Terai M, Hata A.
Cytokine; 2012 Dec 27; 60(3):681-5. PubMed ID: 22944461
[Abstract] [Full Text] [Related]
12. Predictive value of monocyte to HDL-C ratio for coronary artery lesions and intravenous immunoglobulin resistance in Kawasaki disease.
Wang JR, Zhao HZ, Chang LJ, Xu X, Gao Y, Li M, Kong QY, Wang MM, Zhao CF.
Eur J Pediatr; 2023 Oct 27; 182(10):4399-4406. PubMed ID: 37480545
[Abstract] [Full Text] [Related]
13. Clinical relevance of the risk factors for coronary artery lesions in Kawasaki disease.
Weng KP, Hsieh KS, Huang SH, Ou SF, Ma CY, Ho TY, Lai CR, Ger LP.
Kaohsiung J Med Sci; 2012 Jan 27; 28(1):23-9. PubMed ID: 22226058
[Abstract] [Full Text] [Related]
14. Delayed intravenous immunoglobulin treatment increased the risk of coronary artery lesions in children with Kawasaki disease at different status.
Qiu H, He Y, Rong X, Ren Y, Pan L, Chu M, Wu R, Shi H.
Postgrad Med; 2018 May 27; 130(4):442-447. PubMed ID: 29745742
[Abstract] [Full Text] [Related]
15. Infliximab Plus Intravenous Immunoglobulin (IVIG) Versus IVIG Alone as Initial Therapy in Children With Kawasaki Disease Presenting With Coronary Artery Lesions: Is Dual Therapy More Effective?
Jone PN, Anderson MS, Mulvahill MJ, Heizer H, Glodé MP, Dominguez SR.
Pediatr Infect Dis J; 2018 Oct 27; 37(10):976-980. PubMed ID: 29461447
[Abstract] [Full Text] [Related]
16. Serum IL-41 might be a biomarker for IVIG resistance and coronary artery lesions in Kawasaki disease.
Duan Y, Li H, Luo D, Jiang J, Liu B, Li G.
Int Immunopharmacol; 2023 Sep 27; 122():110600. PubMed ID: 37423157
[Abstract] [Full Text] [Related]
17. Aberrantly decreased levels of NKG2D expression in children with kawasaki disease.
Ge X, Li CR, Yang J, Wang GB.
Scand J Immunol; 2013 May 27; 77(5):389-97. PubMed ID: 23298273
[Abstract] [Full Text] [Related]
18. Expression of receptor for advanced glycation end products (RAGE) on the surface of circulating endothelial cells is upregulated in Kawasaki disease.
Gong F, Zhang Y, Xie C, Zhu W, Wang W, Fu S, Shen H.
Pediatr Res; 2012 Jun 27; 71(6):720-4. PubMed ID: 22337222
[Abstract] [Full Text] [Related]
19. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.
Tse SM, Silverman ED, McCrindle BW, Yeung RS.
J Pediatr; 2002 Apr 27; 140(4):450-5. PubMed ID: 12006960
[Abstract] [Full Text] [Related]
20. Altered immunoglobulin A and M levels associated with changes in BAFF and APRIL after administration of intravenous immunoglobulin to treat Kawasaki disease.
Doi M, Takeda T, Sakurai Y, Kato J, Hayashi T, Fukuda K, Takase T, Shima M.
J Investig Allergol Clin Immunol; 2010 Apr 27; 20(5):413-8. PubMed ID: 20945608
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
